Baxdrostat (CIN-107, RO6836191), an orally bioavailable, highly selective aldosterone synthase inhibitor (ASI), has now demonstrated robust blood pressure reduction in phase 3 clinical trials, marking a potential paradigm shift in the management of resistant hypertension. The gene discussed is CYP11B2; the disease is hypertensive disorder.